Literature DB >> 32475934

Edaravone Improves Intermittent Hypoxia-Induced Cognitive Impairment and Hippocampal Damage in Rats.

Jizu Ling1,2, Qin Yu3, Yuning Li1, Xinhui Yuan1, Xiaoya Wang2, Weiying Liu2, Ting Guo3, Yanni Duan3, Lifang Li3.   

Abstract

Oxidative stress plays an essential role in obstructive sleep apnea-hypopnea syndrome-induced cognitive dysfunction in children. This study investigated the effects of edaravone, a potent free radical scavenger, on intermittent hypoxia (IH)-induced oxidative damage and cognition impairment in a young rat model of IH. IH rats were treated with edaravone for 4 weeks. Behavioral testing was performed using the Morris water maze, and hippocampal tissues were harvested for further analyses. Edaravone attenuated IH-induced cognitive impairment, reduced morphological and structural abnormalities, and increased the number of mitochondria in the IH rats. Furthermore, edaravone significantly increased the inhibition of hydroxyl free radicals; reduced expressions of superoxide anion, malondialdehyde, and 8-hydroxy-2'-deoxyguanosine; and upregulated the expression of manganese superoxide dismutase, catalase, cAMP, protein kinase A, phosphorylated-cAMP response element-binding (p-CREB), B-cell lymphoma 2, and brain-derived neurotrophic factor in the hippocampal tissue of IH rats. Our findings suggest that edaravone attenuated IH-induced cognitive impairment and hippocampal damage by upregulating p-CREB in young rats.

Entities:  

Keywords:  cognitive function; edaravone; intermittent hypoxia; obstructive sleep apnea; oxidative stress; young rat

Mesh:

Substances:

Year:  2020        PMID: 32475934     DOI: 10.1248/bpb.b20-00085

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  1 in total

Review 1.  Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection.

Authors:  Sun Joo Cha; Kiyoung Kim
Journal:  Antioxidants (Basel)       Date:  2022-01-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.